Xylitol vs Saline Nasal Irrigations in CF-CRS
NCT: NCT05531630 · ENROLLING_BY_INVITATION
Brief Summary
Cystic fibrosis (CF) is the most common genetic disorder in Belgium, affecting 1 in 2850 children. A defect in the CFTR channel results in increased viscosity of extracellular secretions and decreased mucociliary clearance in the airways. As a result of this mechanism, chronic rhinosinusitis (CRS) occurs in nearly 100% of CF patients. CRS can lead to pronounced sinonasal complaints and can have a negative impact on the quality of life. In addition, several studies have shown that poor upper airway control has a negative impact on the lower airways. Unfortunately, treatment options are limited. Our previous study has shown that only 21% of patients have well-controlled CRS. The aim of this single-center, randomized cross-over study is to compare the effect of nasal rinses with (XNI) and without (SNI) Xylitol in the treatment of CF-CRS. Xylitol is a sugar alcohol that is already used as an antibiofilm agent,eg in the prevention of caries. Previous pilot studies have already shown a beneficial effect of XNI in the treatment of non-CF CRS.
Frequently Asked Questions
What is Xylitol vs Saline Nasal Irrigations in CF-CRS?
Xylitol vs Saline Nasal Irrigations in CF-CRS is a clinical trial registered under NCT05531630. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT05531630?
The current status of NCT05531630 (Xylitol vs Saline Nasal Irrigations in CF-CRS) is: ENROLLING_BY_INVITATION.
When did Xylitol vs Saline Nasal Irrigations in CF-CRS start?
Xylitol vs Saline Nasal Irrigations in CF-CRS started on 2022-12-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.